Skip to main navigation

Home
Overview
News & Publications
News Releases Publications
Events & Presentations
Governance
Documents & Charters Leadership and Board Committee Composition
Stock
Stock Quote & Chart Analyst Coverage
Financials
SEC Filings
IR Resources
Email Alerts Contact Us

Events and Presentations

Corporate Presentation

March 25, 2026

HCW Biologics March 2026 2.6 MB

Past Events

Apr 20, 2026

Development of HCW11-018b (T Cell Engager), An Innovative Approach to Improve Bispecific T-Cell Engagers for Solid Tumor Therapy (Poster presented at AACR Annual Meeting 2026)

Poster Presentation 1 MB

Nov 7, 2025

A Debut of HCWB’s 2nd Gen T-cell Engager IND-Enabling Study Data - 40th SITC2025 Poster

Poster Presentation 1.1 MB

Oct 22, 2025

Video: Dr. Peter Rhode Participated in a Virtual Investor “What This Means” Segment About HCWB’s Second Generation Proprietary Immune Checkpoint Inhibitor

Sep 30, 2025

Video: Dr. Peter Rhode Participated in a Virtual Investor “What This Means” Segment About HCWB’s Second Generation Proprietary T-Cell Engager Program

Jun 27, 2025

2025 Annual Meeting – Replay Instructions

Annual Meeting letter 168.9 KB

Nov 1 - Nov 5, 2023

38th Annual SITC Conference

First-in-Human Clinical Readout of HCW9218, SITC 2023 2.2 MB

Apr 19, 2023

HCW9218 Underlying Mechanism of Action Against Solid Tumors, AACR Annual Meeting 2023

Poster Presentation 1.1 MB

Nov 14, 2022

A Phase 1 Study of HCW9218, a Bifunctional TGF-β Antagonist/IL-15 Protein Complex, in Advanced Solid Tumors, SITC Annual Meeting 2022

Poster Presentation 848.8 KB

May 9, 2022

Robust human regulatory T cell expansion with fusion proteins HCW9302 and HCW9213 circumvents need for magnetic-bead or feeder cell approaches for adoptive cell therapy – Immunology 2022

Robust human regulatory T cell expansion with fusion proteins HCW9302 and HCW9213 circumvents need for magnetic-bead or feeder cell approaches for adoptive cell therapy – Immunology 2022 942.9 KB

May 9, 2022

A “kick and expand” strategy to generate large numbers of CIML NK cells for adoptive cell therapy for the treatment of cancer using novel fusion proteins HCW9201 and HCW9206 – Immunology 2022

A “kick and expand” strategy to generate large numbers of CIML NK cells for adoptive cell therapy for the treatment of cancer using novel fusion proteins HCW9201 and HCW9206 – Immunology 2022 1.1 MB

Pagination

Current page 1
Page 2
Next page
Last page

© HCW Biologics, Inc. 2021 - 2026